Respiratory syncytial virus (RSV) is a major human pathogen causing mild to severe respiratory infec- tions. RSV infection is particularly serious in infants and young children and causes more than 125,000 hospitalizations and 400 deaths among infants annually. Vaccine and treatment options are limited. RSV induced pathology includes damage from both the virus and the host immune response.
In vitro studies are used to test drug candidates for activity against RSV. IBT uses the RSV A2 strain in the well-established Vero and HEp-2 cell lines.